[Translation] A multicenter, randomized, double-blind, positive-drug parallel-controlled clinical trial on the efficacy and safety of neconazole hydrochloride cream in the treatment of tinea pedis

以联苯苄唑乳膏为对照，验证盐酸奈康唑乳膏治疗足癣的有效性和安全性。

[Translation]

Using bifonazole cream as a control, the efficacy and safety of neconazole hydrochloride cream in the treatment of tinea pedis were verified.

Start Date28 Oct 2015

Sponsor / Collaborator

Shandong Bestcomm Pharmaceutical Co., Ltd.

100 Clinical Results associated with Neticonazole Hydrochloride

100 Translational Medicine associated with Neticonazole Hydrochloride

100 Patents (Medical) associated with Neticonazole Hydrochloride

Literatures (Medical) associated with Neticonazole Hydrochloride

01 Oct 2024·Journal of Biological Chemistry

Development of a high throughput cytochrome P450 ligand-binding assay

Article

Author: Scott, Emily E. ; Frydendall, Elyse K ; Frydendall, Elyse ; Scott, Emily E

Human cytochrome P450 enzymes are membrane-embedded monooxygenases responsible for xenobiotic metabolism, steroidogenesis, fatty acid metabolism, and vitamin metabolism. Their active sites can accommodate diverse small molecules and understanding these interactions is key to decoding enzymatic functionality and designing drugs. The most common method for characterizing small molecule binding is quantifying absorbance changes that typically occur when ligands enter the active site near the heme iron. Traditionally, such titrations are monitored by a spectrophotometer, requiring significant manual time, protein, and increasing solvents. This assay was adapted for semi-automated high throughput screening, increasing throughput 50-fold while requiring less protein and keeping solvent concentrations constant. This 384-well assay was validated for both type I and II shifts typically observed for substrates and heme-coordinating inhibitors, respectively. This assay was used to screen a library of ∼100 diverse imidazole-containing compounds which can coordinate with the heme iron if compatible with the overall active site. Three human cytochrome P450 enzymes were screened: drug-metabolizing CYP2A6 and CYP2D6 and sterol-metabolizing CYP8B1. Each bound different sets of imidazole compounds with varying K_d values, providing a unique binding fingerprint. As a final validation, the K_d values were used to generate pharmacophores to compare to experimental X-ray structures. Applications for the high-throughput assay include the following: 1) facilitating generation of pharmacophores for enzymes where structures are not available, 2) screening to identify ligands for P450 orphans, 3) screening for inhibitors of P450s drug targets, 4) screening potential new drugs to avoid and/or control P450 metabolism, and 5) efficient validation of computational ligand binding predictions.

21 Apr 2021·Journal of Agricultural and Food ChemistryQ1 · AGRICULTURAL & FORESTRY SCIENCE

Multiclass Analytical Method for Pesticide and Mycotoxin Analysis in Malt, Brewers’ Spent Grain, and Beer: Development, Validation, and Application

Q1 · AGRICULTURAL & FORESTRY SCIENCE

Article

Author: Gonçalves, José Ailton ; Pires, Nilsrael Alves ; Gonçalves De Oliveira, Mauro Lucio ; Faria, Adriana Ferreira

A multiclass analytical method to determine pesticides and mycotoxins in beer-related matrices based on the dilute and shoot approach was optimized and validated according to the European guidelines SANTE/12682/2019 and EC/401/2006. Extraction used acidified acetonitrile at 1% (v/v) acetic acid, followed by horizontal shaking homogenization, centrifugation, freeze-out step for cleanup, another centrifugation, and injection into a high-performance liquid chromatography-tandem mass spectrometry system. Linearity, detection and quantification limits, accuracy, and measurement uncertainty were evaluated, and 201, 184, and 176 analytes were validated for malt, beer, and brewers' spent grain, respectively. The limits of quantification ranged between 1 and 200 μg kg^-1 and between 5 and 1000 μg kg^-1 for beer and malt, respectively, and expanded uncertainties ranged between 9.7 and 50%, meeting the legislation requirements. A total of 40 samples have been analyzed thus far, and 36 of them exhibited the presence of some of the analyzed substances. The validated method is reliable and easy to apply for mycotoxin and pesticide determination in complex matrices.

01 Apr 2020·Investigational New DrugsQ3 · MEDICINE

The exosome secretion inhibitor neticonazole suppresses intestinal dysbacteriosis-induced tumorigenesis of colorectal cancer

Q3 · MEDICINE

Article

Author: Li, Cong ; Gu, Lei ; Xu, Wangyan ; Li, Meng ; Xu, Yidong ; Su, Hui ; Liu, Zhongchen

Colorectal cancer (CRC) is the most frequently encountered malignancy associated with the rectum or colon, and accumulating evidences have implicated intestinal dysbacteriosis (IDB, disruption of gut microbiome) and exosomes in the pathology of CRC. We aimed to investigate the effect of IDB on exosome secretion in a CRC xenograft mouse model. An IDB mouse model was established and was inoculated with the CRC cell line SW480 as a xenograft tumor. Tumor growth was monitored for 15 days in sham and IDB mice, after which blood was collected to assess serum exosome secretion. A novel exosome secretion inhibitor, neticonazole, was administered to IDB mice bearing CRC xenograft tumors, followed by monitoring of tumor growth and mouse survival. Western blot analysis was performed in xenograft tumors to investigate the underlying molecular mechanism. IDB promoted CRC xenograft tumor growth and exosome secretion, which could be inhibited by the exosome secretion inhibitor neticonazole. Moreover, neticonazole treatment significantly improved the survival of IDB mice with CRC xenograft tumors, likely through increasing apoptosis of CRC xenograft tumor cells. The exosome secretion inhibitor neticonazole may serve as a promising therapeutic candidate against CRC by suppressing IDB-induced CRC tumorigenesis.

100 Deals associated with Neticonazole Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D01620	Neticonazole Hydrochloride	D01A	-

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Candidiasis, Cutaneous	Japan	Hisamitsu Pharmaceutical Co., Inc.	04 Jul 2003
Tinea corporis	Japan	Hisamitsu Pharmaceutical Co., Inc.	04 Jul 2003
tinea cruris	Japan	Hisamitsu Pharmaceutical Co., Inc.	04 Jul 2003
Tinea Pedis	Japan	Hisamitsu Pharmaceutical Co., Inc.	04 Jul 2003
Tinea Versicolor	Japan	Hisamitsu Pharmaceutical Co., Inc.	04 Jul 2003

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis